EMA To Revisit Rejection Of Elzonris & Gamifant
Executive Summary
A much slimmed-down August agenda for the European Medicines Agency’s drug assessment body, the CHMP, also shows that Janssen has asked for more time to reply to questions about its potential multiple sclerosis therapy, ponesimod.
You may also be interested in...
Companies Get Yet More Time To Assess Nitrosamine Risk In EU
After EU regulators decided that biological medicines should be reviewed for the presence of possible nitrosamine impurities – as is already required for chemical medicines – new deadlines have been agreed on to give companies enough time to comply.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.